<div id="readability-page-1"><p>Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the fourteen brokerages that are presently  covering the stock, Marketbeat.com reports. One equities research analyst  has rated the stock with a sell recommendation, one  has assigned  a hold recommendation and twelve have given a buy recommendation to  the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $22.5556.</p><div><p><span></span><span>Get <strong>Ocular Therapeutix</strong> alerts:</span></p></div><p>A number of research firms recently weighed in on OCUL. Cowen  reaffirmed a &#34;buy&#34; rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Chardan Capital  reaffirmed a &#34;buy&#34; rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 9th. Robert W. Baird increased their price objective on Ocular Therapeutix from $17.00 to $24.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, October 3rd. HC Wainwright lifted their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, December 8th. Finally, Zacks Research upgraded Ocular Therapeutix from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, October 2nd.</p><p><b>Read Our Latest Analysis on OCUL</b></p><h2>Ocular Therapeutix Stock Down 0.7%</h2><p>Shares of NASDAQ OCUL opened at $14.56 on Monday. The company has a quick ratio of 7.78, a current ratio of 7.85 and a debt-to-equity ratio of 0.27. The company has a market cap of $3.10 billion, a P/E ratio of -10.11 and a beta of 0.96. Ocular Therapeutix has a 52 week low of $5.78 and a 52 week high of $16.44. The business has a 50-day simple moving average of $12.01 and a two-hundred day simple moving average of $11.41. </p><p>Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%.The firm had revenue of $14.54 million for the quarter, compared to analysts' expectations of $14.57 million.  Research analysts anticipate that  Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In related news, insider Jeffrey S. Heier sold 10,502 shares of the company's stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total value of $115,942.08. Following the transaction, the insider directly owned 249,409 shares in the company, valued at approximately $2,753,475.36. This represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Peter Kaiser sold 9,653 shares of the business's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the transaction, the insider directly owned 194,440 shares of the company's stock, valued at approximately $2,144,673.20. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 31,287 shares of company stock worth $359,784. Insiders own  2.30% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. purchased a new stake in  Ocular Therapeutix during the third quarter valued at about $2,360,000.  CIBC Bancorp USA Inc. bought a new position in shares of  Ocular Therapeutix during the 3rd quarter valued at about $175,000.  Maven Securities LTD purchased a new position in shares of  Ocular Therapeutix during the 3rd quarter valued at about $1,169,000.  Second Line Capital LLC raised its holdings in shares of  Ocular Therapeutix by 4.4% during the 3rd quarter. Second Line Capital LLC now owns 402,467 shares of the biopharmaceutical company's stock valued at $4,705,000 after buying an additional 17,000 shares in the last quarter.  Finally, CANADA LIFE ASSURANCE Co lifted its position in  Ocular Therapeutix by 17.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 31,914 shares of the biopharmaceutical company's stock worth $400,000 after buying an additional 4,729 shares during the last quarter. Institutional investors own  59.21% of the company's stock. </p><h2>Ocular Therapeutix Company Profile</h2> (Get Free Report)<p>Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Ocular Therapeutix</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>How to Calculate Options Profits</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>What Are Dividend Champions? How to Invest in the Champions</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ocular Therapeutix Right Now?</h2><p>Before you consider Ocular Therapeutix, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.</p><p>While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OCUL

<p>Ocular Therapeutix, Inc. (NASDAQ:OCUL) has received a "Moderate Buy" consensus rating from 14 brokerages, with an average 12-month price target of $22.56. The stock has a 52-week range of $5.78 to $16.44. Recent insider sales and institutional investments have been noted. The company reported a quarterly loss of $0.37 per share, slightly better than expected, with revenue of $14.54 million. Insiders own 2.30% of the stock, while institutional investors hold 59.21%.</p>

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts